<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019743</url>
  </required_header>
  <id_info>
    <org_study_id>A70_07BE1906P</org_study_id>
    <nct_id>NCT04019743</nct_id>
  </id_info>
  <brief_title>Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Fasted, Single Dose, Crossover Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, open-label, fasted, single dose, crossover study to investigate
      the pharmacokinetic profiles and safety of CKD-333 in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To healthy subjects of twenty-four (24), following treatments are administered dosing in each
      period and wash-out period is a minimum of 14 days.

      Reference drug: 1) CKD-330 16/10mg Tab. 2) D086 Tab. Test drug: 1) CKD-333 16/10/40mg
      formulation 1 Tab. 2) CKD-333 16/10/40mg formulation 2 Tab.

      Pharmacokinetic blood samples are collected up to 72hrs. The pharmacokinetic characteristics
      and safety are assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 28, 2019</start_date>
  <completion_date type="Actual">September 4, 2019</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of CKD-330, D086, CKD-333</measure>
    <time_frame>Pre-dose (0 hour), post-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
    <description>Area under the CKD-330/D086/CKD-333 concentration in blood-time curve from zero to final</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of CKD-330, D086, CKD-333</measure>
    <time_frame>Pre-dose (0 hour), post-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
    <description>The maximum CKD-330/D086/CKD-333 concentration in blood sampling time t</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hypertension</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment A
Period 2: Treatment B
Period 3: Treatment C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment C
Period 2: Treatment A
Period 3: Treatment B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment B
Period 2: Treatment C
Period 3: Treatment A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment C
Period 2: Treatment B
Period 3: Treatment A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment B
Period 2: Treatment A
Period 3: Treatment C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment A
Period 2: Treatment C
Period 3: Treatment B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-330 16/10mg Tab. 1T and D086 Tab. 1T</intervention_name>
    <description>single oral administration under fasting condition</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Treatment A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-333 16/10/40mg formulation 1 Tab. 1T</intervention_name>
    <description>single oral administration under fasting condition</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Treatment B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-333 16/10/40mg formulation 2 Tab. 1T</intervention_name>
    <description>single oral administration under fasting condition</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Treatment C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 19 to 55 years old healthy subject at the screening

          2. Individuals who had 17.5 kg/m2 ≤ Body Mass Index(BMI) &lt; 30.5kg/m2 and a total body
             weight ≥ 55 kg

             * BMI = Weight(kg)/ Height(m)2

          3. Individuals without congenital/chronic diseases and without abnormal symptoms or
             diagnosis based on a medical examination within the last 3 years

          4. Individuals who were deemed to be appropriate as study subjects in accordance with the
             screening results (laboratory tests, vital signs, ECG etc.)

          5. Individuals who signed an informed consent form approved by the IRB of Chonbuk
             National University Hospital and decided to participate in the study after being fully
             informed of the study prior to participation, including the objective, content and
             characteristics of the investigational drug

          6. Individuals who agreed proper contraception during the study and did consent to not
             donation of sperm 1 month after the last dose of study drug infusion

          7. Individuals with the ability and willingness to participate during the study period

        Exclusion Criteria:

          1. Individuals with a medical evidence or history of clinically significant
             hematological, renal, endocrine, pulmonary, gastrointestinal, urinary, cardiovascular,
             hepatic, psychiatric, neurologic or immune disease (excluding simple dental history
             such as dental calculus, impacted tooth, wisdom tooth, etc.)

          2. Individuals with a medical history of gastrointestinal disease (e.g., gullet disease
             including esophageal achalasia, esophagostenosis, or Crohn's disease) or operations
             (excluding simple appendectomy, herniotomy, or tooth extraction surgery) that may
             affect drug absorption

          3. Individuals with the following laboratory test results:

               -  ALT or AST &gt; 2x the upper limit of the normal range

               -  CK &gt; 3x the upper limit of the normal range

          4. A history of regular alcohol consumption exceeding 210 g/week within the 6 months
             prior to screening (1 drink (250 mL) of beer (5%) = 10 g; 1 drink (50 mL) of hard
             liquor (20%) = 8 g; 1 drink (125 mL) of wine (12%) = 12 g)

          5. Individuals who smoked more than 20 cigarettes per day within 6 months prior to
             screening

          6. Individuals who had been administered investigational product(s) of other clinical
             study or bioequivalence study within the 6 months prior to the first dose of this
             study

          7. Individuals with the following vital signs results at screening Individuals who had
             sitting blood pressure ≥90 mmHg or &lt;140 mmHg (systolic) or ≥90 mmHg or &lt;60 mmHg
             (diastolic)

          8. Individuals with a medical history of significant alcohol abuse or drug abuse within
             one year prior to the screening

          9. Individuals who had taken any drug(s) known as a strong inducer(s) or inhibitor(s) of
             drug-metabolizing enzymes within 30 days prior to the first dose of investigational
             product(s)

         10. Individuals who had taken prescription or nonprescription drugs within the 10 days
             prior to the first dose of investigational product(s)

         11. Individuals who donated whole blood within the 2 months, or blood components within 1
             month prior to the first dose of the investigational product(s)

         12. Individuals with severe acute/chronic medical or psychiatric conditions that may
             increase the risk associated with study participation or investigational product(s)
             administration, or may interfere with the interpretation of study results

         13. Individuals with hypersensitivity to ingredients used in the investigational
             product(s)

         14. Patient with hyperkalemia

         15. Patients with hepatopathy

         16. Patients with hereditary angioedema, ACE inhibitors or angiotensin Ⅱ receptor
             antagonists who have a history of angioedema

         17. Primary hyperaldosteronism

         18. Patients with aortic valve stenosis, mitral (valve) stenosis, hypertrophic obstructive
             cardiomyopathy

         19. Patients with ischemic heart disease, ischemic cardiovascular disease, cerebrovascular
             disease

         20. Patients with Intravascular volume depletion

         21. Patients with nephropathy (eGFR&lt;60 ml/min/1.73 m2)

         22. Patients with renal artery stenosis

         23. Patients with muscle disease

         24. Patients with Hypothyroidism

         25. Women who are pregnant or may be pregnant

         26. Patients with a history of muscle toxicity when using statins or fibrates

         27. Patients with hereditary diseases of galactose intolerance, Lapp lactase deficiency or
             glucose-galactose malabsorption etc.

         28. Individuals who were deemed to be inappropriate to participate in the study by the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju, South Korea</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

